ICG vs Blue Patent for TAD in cN1 Breast Carcinoma After Neoadjuvant Chemotherapy
Recruiting · NCT06339658 · Observational (researchers observe without assigning treatment) · Lead sponsor: Hospital Universitari de Bellvitge
View the official record on ClinicalTrials.gov →Interventions studied
Targeted axillary dissection (TAD) by Blue patentTargeted axillary dissection (TAD) by ICG
What this trial is about
To validate the use of ICG as a tracer during TAD in patients with cN1 breast carcinoma after neoadjuvant chemotherapy.
Who can take part
Age range
18 Years and older
Sex
Female
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Breast cancer cN+ patients who undergo neadjuvant treatment.
Exclusion criteria
- Patients in whom there is a contraindication for the use of ICG.
- Patients in whom there is evidence of progression of the disease after neoadjuvant treatment.
Where it is running
1 location listed.
- Hospital de Bellvitge - L'Hospitalet de Llobregat, Barcelona, Spain